Literature DB >> 22228332

Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.

Florian Grabellus1, James Nagarajah, Andreas Bockisch, Kurt Werner Schmid, Sien-Yi Sheu.   

Abstract

PURPOSE: Glucose transporters 1 (GLUT1) facilitates glucose uptake in cancer. An inverse relationship between I-131 and F-18 fluorodeoxyglucose (FDG) uptake in PET/CT ("flip-flop phenomenon") was described for thyroid cancers (TCs) during dedifferentiation. We investigated the relationship among GLUT1 expression, proliferation, iodine concentration, and glucose uptake in different TC types, with emphasis on "poorly differentiated thyroid carcinoma" (PDTC).
METHODS: For immunohistochemistry, 95 thyroid tumors (follicular adenoma, papillary TC, follicular TC, PDTC, and anaplastic TC [ATC]) were investigated for GLUT1 expression and proliferation (Ki-67 index). For PET/CT study, 47 F-18 FDG PET/CT of patients with TC (22 PDTC), 39 corresponding I-124 PET/CT, and glucose and iodine uptake were evaluated. PTC and FTC were summarized under differentiated TC (DTC).
RESULTS: Immunohistochemistry: 65% of TC expressed GLUT1. The number of GLUT1-positive TC and GLUT1 expression increased with escalating dedifferentiation/aggressiveness of TC types (P < 0.001). A correlation between proliferation and GLUT1 expression was noted (P < 0.001). PET/CT study: F-18 FDG uptake was measured in 81% of cases. Occurrence of F-18 FDG-avid cases as well as median F-18 FDG maximum standardized uptake values were lowest in DTC, intermediate in PDTC, and highest in ATC. Accordingly, numbers of iodine-avid cases and median I-124 maximum standardized uptake value featured an inverse pattern.
CONCLUSIONS: Dedifferentiation in TC is accompanied by GLUT1 upregulation and increased proliferation. PDTC was found to be intermediate between DTC and ATC in terms of GLUT1 expression and F-18 FDG or I-124 uptake, suggesting that the flip-flop phenomenon occurs at a dedifferentiation stage in between. Furthermore, the results suggest that F-18 FDG PET/CT is an important imaging modality for ATC and PDTC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228332     DOI: 10.1097/RLU.0b013e3182393599

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  39 in total

1.  Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.

Authors:  James Nagarajah; Alan L Ho; R Michael Tuttle; Wolfgang A Weber; Ravinder K Grewal
Journal:  J Nucl Med       Date:  2015-03-26       Impact factor: 10.057

2.  Comment on Rosenbaum-Krumme et al.: (18)F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.

Authors:  Francesco Bertagna; Raffaele Giubbini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-07-18       Impact factor: 9.236

Review 3.  The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview.

Authors:  Giorgio Treglia; Barbara Muoio; Luca Giovanella; Massimo Salvatori
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-10-02       Impact factor: 2.503

4.  Bilateral Renal Metastasis of Hürthle Cell Thyroid Cancer with Discordant Uptake Between I-131 Sodium Iodide and F-18 FDG.

Authors:  Apichaya Claimon; Minseok Suh; Gi Jeong Cheon; Dong Soo Lee; E Edmund Kim; June-Key Chung
Journal:  Nucl Med Mol Imaging       Date:  2016-12-09

5.  Can the American Thyroid Association Risk of Recurrence Predict Radioiodine Refractory Disease in Differentiated Thyroid Cancer?

Authors:  Aamna Hassan; Saima Riaz; Humayun Bashir; M Khalid Nawaz; Raza Hussain
Journal:  Eur Thyroid J       Date:  2016-10-21

6.  Correlation of BRAF mutation and SUVmax levels in thyroid cancer patients incidentally detected in 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Aysenur Ozderya; Sule Temizkan; Aylin Ege Gul; Sule Ozugur; Mehmet Sargin; Kadriye Aydin
Journal:  Endocrine       Date:  2016-10-01       Impact factor: 3.633

Review 7.  Glucose transporters in cancer metabolism.

Authors:  Kehinde Adekola; Steven T Rosen; Mala Shanmugam
Journal:  Curr Opin Oncol       Date:  2012-11       Impact factor: 3.645

8.  The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.

Authors:  Martin Barrio; Johannes Czernin; Michael W Yeh; Miguel F Palma Diaz; Pawan Gupta; Martin Allen-Auerbach; Christiaan Schiepers; Ken Herrmann
Journal:  Nucl Med Commun       Date:  2016-12       Impact factor: 1.690

9.  F18-FDG-PET/CT thyroid incidentalomas: a wide retrospective analysis in three Italian centres on the significance of focal uptake and SUV value.

Authors:  Francesco Bertagna; Giorgio Treglia; Arnoldo Piccardo; Elisabetta Giovannini; Giovanni Bosio; Giorgio Biasiotto; El Khayat Bahij; Roberto Maroldi; Raffaele Giubbini
Journal:  Endocrine       Date:  2012-11-21       Impact factor: 3.633

10.  [18F]-FDG-PET/CT and [18F]-FAZA-PET/CT Hypoxia Imaging of Metastatic Thyroid Cancer: Association with Short-Term Progression After Radioiodine Therapy.

Authors:  Masatoyo Nakajo; Megumi Jinguji; Atsushi Tani; Yoriko Kajiya; Tooru Nandate; Ikumi Kitazano; Takashi Yoshiura
Journal:  Mol Imaging Biol       Date:  2020-12       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.